Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.

SG&A Expenses: Ultragenyx vs. Verona Pharma Over a Decade

__timestampUltragenyx Pharmaceutical Inc.Verona Pharma plc
Wednesday, January 1, 2014108110001802274
Thursday, January 1, 2015330010002512761
Friday, January 1, 2016649360002894488
Sunday, January 1, 2017999090008096274
Monday, January 1, 20181277240007985229
Tuesday, January 1, 20191615240008994597
Wednesday, January 1, 202018293300029772000
Friday, January 1, 202121998200033907000
Saturday, January 1, 202227813900026579000
Sunday, January 1, 202330979900049868547
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, Ultragenyx's SG&A expenses surged by nearly 2,800%, reflecting its aggressive expansion and market penetration strategies. In contrast, Verona Pharma's expenses grew by approximately 2,700%, indicating a more measured approach to scaling operations. Notably, in 2023, Ultragenyx's expenses were about six times higher than Verona Pharma's, highlighting the differing scales and strategies of these two companies. This financial snapshot provides a window into how these biotechs allocate resources to support their growth and innovation efforts. As the industry evolves, understanding these financial dynamics becomes essential for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025